Vir Biotechnology Inc (VIR) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

VIR ranks #2587 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

VIR is a top-conviction position for GSK plc — at 14.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in VIR belongs to BlackRock, Inc., but the position matters far more to GSK plc, who has 14.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Vontobel Holding Ltd. has added to its VIR position for two straight quarters, increasing it by $107.1K to reach $403.2K today.

State of Alaska, Department of Revenue has trimmed its VIR position for two straight quarters, cutting it by $267.0K while still holding $238.0K.

VIR is down 4.9% today, but institutions show net buying of $124.8M this quarter — a divergence between today's price move and the underlying institutional flow.

VIR reported a net loss of $251.7M over the trailing twelve months.

• Not yet profitable — net loss of $251.7M over the trailing twelve months
• Revenue grew 1495.9% year over year
• Net income improved year over year, from -$550.2M to -$251.7M
• Operating cash flow was negative, using $391.8M in cash
• Current ratio of 5.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.31x equity — within a conventional range